• 1. Aromatic C-nitrosation of a bioactive molecule. Nitrosation of minoxidil
  Mario González-Jiménez,Jorge Arenas-Valga?ón,Emilio Calle,Julio Casado Org. Biomol. Chem. 2011 9 7680
• 2. One-step construction of ferritin encapsulation drugs for cancer chemotherapy
  Ippei Inoue,Mayumi Chiba,Kenichiro Ito,Yoriko Okamatsu,Yasuyo Suga,Yoshiro Kitahara,Yuichi Nakahara,Yuta Endo,Kazutoshi Takahashi,Uno Tagami,Naofumi Okamoto Nanoscale 2021 13 1875

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines
• Pharmaceutical and Biochemical Products

Minoxidil (CAS No. 38304-91-5): A Comprehensive Overview of Its Mechanism, Applications, and Recent Research Developments

Minoxidil, chemically identified by the CAS number 38304-91-5, is a well-known compound in the field of pharmaceuticals and dermatology. Originally developed as an antihypertensive agent, its unique pharmacological properties have led to its widespread use in treating hair loss and promoting hair growth. This introduction delves into the molecular structure, pharmacological mechanisms, clinical applications, and the latest research findings surrounding Minoxidil.

The molecular formula of Minoxidil is C₆H₉N₃O₂, and it belongs to the class of imidazole derivatives. Its chemical structure features a nitro group and an imidazole ring, which are crucial for its biological activity. The nitro group contributes to its vasodilatory effects, while the imidazole ring interacts with specific enzymes and receptors in the body.

The primary mechanism of action of Minoxidil involves the stimulation of hair follicle growth. It works by relaxing blood vessels, which increases blood flow to the scalp. This enhanced circulation is believed to promote the growth phase of hair follicles and prevent them from entering the shedding phase. Additionally, Minoxidil has been shown to inhibit certain enzymes that contribute to hair loss, such as 5-alpha-reductase.

One of the most significant clinical applications of Minoxidil is in the treatment of androgenetic alopecia (AGA), commonly known as male pattern baldness. Numerous clinical trials have demonstrated its efficacy in promoting hair regrowth and preventing further hair loss. The U.S. Food and Drug Administration (FDA) has approved topical formulations of Minoxidil for the treatment of AGA in both men and women.

In recent years, research on Minoxidil has expanded beyond its traditional use in dermatology. Studies have explored its potential benefits in other areas, such as wound healing and skin regeneration. For instance, a study published in the *Journal of Dermatological Science* found that topical application of Minoxidil accelerates wound closure by enhancing collagen production and angiogenesis.

The pharmacokinetics of Minoxidil are complex due to its poor systemic absorption when applied topically. However, recent advancements in drug delivery systems have improved its bioavailability. Nanoparticle-based formulations and transdermal patches have been developed to enhance the penetration of Minoxidil into the scalp, thereby increasing its therapeutic efficacy.

Evidence from preclinical studies suggests that Minoxidil may also have neuroprotective properties. Research indicates that it can cross the blood-brain barrier and protect against neurodegenerative diseases such as Alzheimer's disease. While further studies are needed to confirm these findings, they open up new avenues for exploring its potential applications in neurology.

The side effects associated with Minoxidil are generally mild and include irritation, redness, and itching at the application site. In some cases, excessive hair growth on areas adjacent to the scalp has been reported. It is important to note that individual responses to Minoxidil can vary, and patients should consult with a healthcare professional before starting treatment.

The future direction of research on Minoxidil includes investigating its role in combination therapies with other hair growth promoters and exploring novel delivery systems to optimize its efficacy. Additionally, studies are being conducted to understand the long-term effects of chronic use of topical formulations of Minoxidil.

In conclusion, Minoxidil (CAS No. 38304-91-5) is a versatile compound with significant applications in dermatology and potentially other medical fields. Its ability to promote hair growth has made it a cornerstone in treating AGA, while ongoing research continues to uncover new therapeutic possibilities. As our understanding of its mechanisms and applications evolves, so too will its role in modern medicine.

• 83540-15-2(2,4-Pyrimidinediamine,6-[1,4'-bipiperidin]-1'-yl-, 3-oxide, hydrochloride (1:2))
• 142886-74-6(2,4-Pyrimidinediamine, 5-fluoro-6-(1-piperidinyl)-, 3-oxide)
• 158473-55-3((2E)-6-amino-2-imino-4-(piperidin-1-yl)pyrimidin-1(2H)-ol 2,3-dihydroxybutanedioate (1:1))
• 60928-34-9(4-Pyrimidinamine,2,3-dihydro-3-hydroxy-2-imino-6-(4-thiomorpholinyl)-(9CI))
• 68163-26-8(2,4-Pyrimidinediamine, 6-(3-azabicyclo[3.2.2]non-3-yl)-, 3-oxide)
• 55921-65-8(2,6-Diamino-4-(pyrrolidin-1-yl)pyrimidine 1-oxide)
• 55921-62-5(N4,N4-DIPROPYL-1-OXY-PYRIMIDINE-2,4,6-TRIAMINE)
• 68020-78-0(2,4-Pyrimidinediamine, 6-(3,6-dihydro-1(2H)-pyridinyl)-, 3-oxide)
• 1020718-66-4(Minoxidil-d10)
• 83540-32-3(2,4-Pyrimidinediamine,6-(4-methyl-1-piperazinyl)-, 3-oxide, hydrochloride (1:2))